Sun Pharmaceutical Industries Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is NALOXONE HYDROCHLORIDE DIHYDRATE USP, with a corresponding US DMF Number 23389.
Remarkably, this DMF maintains an Active status since its submission on February 22, 2010, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of January 14, 2020, and payment made on January 09, 2020, indicating their dedication to facilitating drug approvals, Categorized as Type II